The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
July 26, 2021
Setmelanotide (Imcivree) for Rare Genetic Forms of Obesity (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Setmelanotide (Imcivree) for Rare Genetic Forms of Obesity (online only)
July 26, 2021 (Issue: 1629)
The FDA has approved setmelanotide (Imcivree –
Rhythm), a subcutaneously injected melanocortin 4
(MC4) receptor agonist, for chronic weight management
in patients ≥6 years old with obesity due to
pro-opiomelanocortin (POMC) deficiency,...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.